Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review

Asia-Pacific Journal of Clinical Oncology

Volumn 9, Issue 4, 2013, Pages 357-364

  Zhao, Yan ^a   Cai, Guohong ^a   Zhou, Lin ^a   Liu, Lei ^a   Qi, Xingshun ^a   Bai, Ming ^a   Li, Yongping ^a   Fan, Daiming ^a   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced hepatocellular carcinoma; Transarterial chemoembolization; Treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; IOHEXOL; LOBAPLATIN; MITOMYCIN;

ABDOMINAL PAIN; ANEMIA; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL EFFECTIVENESS; EXTRAHEPATIC METASTASIS; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; METASTASIS; MORTALITY; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PARALYTIC ILEUS; PLEURA EFFUSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TUMOR INVASION; TUMOR THROMBUS; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; VASCULARIZATION;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84888024920     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12081     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J etal. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
3. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
4. Forner A, Reig ME, de Lope CR etal. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
5. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
6. Camma C, Schepis F, Orlando A etal. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
7. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
8. Lewandowski RJ, Mulcahy MF, Kulik LM etal. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255: 955-965.
9. Lee HS, Kim JS, Choi IJ etal. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997; 79: 2087-2094.
10. Chung GE, Lee JH, Kim HY etal. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634.
11. Luo J, Guo RP, Lai EC etal. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-420.
12. Niu ZJ, Ma YL, Kang P etal. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012; 29: 2992-2997.
13. Yoo DJ, Kim KM, Jin YJ etal. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 2011; 26: 145-154.
14. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
15. Raoul JL, Sangro B, Forner A etal. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220.
16. Chung JW, Park JH, Han JK etal. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995; 165: 315-321.
17. Uraki J, Yamakado K, Nakatsuka A etal. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol 2004; 51: 12-18.
18. Georgiades CS, Hong K, D'Angelo M etal. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659.
19. Kim JH, Yoon HK, Kim SY etal. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29: 1291-1298.
20. Kim KM, Kim JH, Park IS etal. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009; 24: 806-814.
21. Carr BI, Irish W, Federle MP. Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. Hepatogastroenterology 2010; 57: 1375-1381.
22. Kim HY, Kim JD, Bae SH etal. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010; 16: 355-361.
23. Peng ZW, Guo RP, Zhang YJ etal. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012; 118: 4725-4736.
24. Pinter M, Hucke F, Graziadei I etal. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263: 590-599.
25. Kudo M, Izumi N, Kokudo N etal. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
26. Omata M, Lesmana LA, Tateishi R etal. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
27. Okusaka T, Okada S, Ishii H etal. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 1997; 44: 251-257.
28. Uka K, Aikata H, Takaki S etal. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-420.
29. Senthilnathan S, Memon K, Lewandowski RJ etal. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology 2012; 55: 1432-1442.
30. Duerden M. From a cancer drug fund to value based pricing of drugs. BMJ 2010; 341: c4388.
31. Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
32. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
33. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
34. Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol 2011; 29: 3949-3952.